And their entry into the market drives down brand name prices by another 25%. That's real relief for patients, families, and for the American taxpayer. But America still lags far behind Europe and other nations. In Europe, for example, regulators have approved more than twice as many biosimilars as the United States. And patients there are paying far less for many of these treatments. These reforms reflect President Trump's directive to restore competition to empower patients and lower drug costs for every American. (06:37–06:44)
CLAIM
Asserts that Europe has approved significantly more biosimilars compared to the U.S.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
